|Videos|April 6, 2023

IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

Author(s)Shaji Kumar, MD, Mayo Clinic, Sandy Wong, MD, Alexander Lesokhin, MD

The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.

Episodes in this series

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 1 GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 2 Treatment Approaches in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 3 Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 4 Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 5 Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 6 Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 7 Comparing Quadruplet Combination Treatment Regimens in NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 8 Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 9 Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

EP. 10 IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

September 18th, 2026

NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma

Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.

Treatment Strategies in Multiple Myeloma are Changing: © stock_acc - stock.adobe.com

September 12th, 2026

Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma

Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

Trending on CancerNetwork

FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test

Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy

Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC

FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC